{"id":"NCT05291598","sponsor":"University of Miami","briefTitle":"Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)","officialTitle":"IV Meloxicam for Pain Management Post TJA: Prospective Randomized Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-01","primaryCompletion":"2023-05-01","completion":"2023-05-01","firstPosted":"2022-03-22","resultsPosted":"2024-08-14","lastUpdate":"2024-08-14"},"enrollment":223,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Total Knee Replacement","Total Hip Replacement"],"interventions":[{"type":"DRUG","name":"IV meloxicam","otherNames":[]},{"type":"DRUG","name":"Ketorolac","otherNames":[]}],"arms":[{"label":"Ketorolac group","type":"ACTIVE_COMPARATOR"},{"label":"IV meloxicam group","type":"EXPERIMENTAL"}],"summary":"The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).","primaryOutcome":{"measure":"Pain Measured by the Numeric Rating Scale","timeFrame":"2 hours postoperatively","effectByArm":[{"arm":"Ketorolac Group","deltaMin":3.34,"sd":3.25},{"arm":"IV Meloxicam Group","deltaMin":3.32,"sd":3.39}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":114},"commonTop":[]}}